BIIB Stock Analysis: Buy, Sell, or Hold?
BIIB - Biogen Inc. Common Stock
$216.78
2.43 (1.13%)
▲
5d:
+3.31%
30d:
+8.06%
90d:
+14.41%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 29, 2026
0d
Get Alerted When BIIB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BIIB shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BIIB shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$379.99
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$235.95
8.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BIIB is currently trading at $216.78, which is considered extended relative to its 30-day fair value range of $201.21 to $212.19. From a valuation perspective, the stock is trading at a premium (Forward PE: 13.1) compared to its historical average (11.8). At these levels, the market is pricing in 3.6% annual earnings growth.
Technical Outlook: Technically, BIIB is in a strong uptrend. The price is approaching resistance at $222.15. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BIIB scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BIIB is in a strong uptrend. The price is approaching resistance at $222.15. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BIIB scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$201.21 -
$212.19
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
41.2%
Protect Your Profits
Holding BIIB? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($235.57)
- BULLISH: Expecting earnings turnaround to 3.6% growth with 3.4% revenue growth
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$201.21 -
$212.19
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$9.78
(4.5%)
Support & Resistance Levels
Support Level
$201.00
Resistance Level
$222.15
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.11
Wall Street Target
$235.57
(+8.7%)
Revenue Growth (YoY)
3.4%
Earnings Growth (YoY)
-84.8%
Profit Margin
8.3%
Valuation Premium vs History
+3.6% premium
PE vs Historical
13.1 vs 11.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.6%
(market-implied from PE analysis)
1-Year Target
$224.58
(+4%)
2-Year Target
$232.67
(+7%)
3-Year Target
$241.05
(+11%)
3-Yr Target (if PE normalizes)
(PE: 13→12)
PE COMPRESSION
$216.98
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 33.2%)
$784.87
(+262%)
Base:
(SPY PE: 13.1, Growth: 33.2%)
$512.65
(+137%)
Bear:
(PE: 11.1, Growth: 33.2%)
$435.75
(+101%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (39x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 39.40 | Current EPS (TTM): $5.44
Bull Case
$471.57
(+118%)
Analyst growth 100.0%, PE expands to 43.3
Base Case
$428.70
(+98%)
Market implied 100.0%, PE stable at 39.4
Bear Case
$145.76
(-33%)
Severe decline -20.0%, PE contracts to 33.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 23, 2026 2:10 AM ET
Data refreshes hourly during market hours. Next update: 3:10 AM
Data refreshes hourly during market hours. Next update: 3:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIIB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1311 | 37 SELL |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 34 SELL |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$276 | 41 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$384 | 38 SELL |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$138 | 45 HOLD |
Advanced BIIB Option Strategies
Professional options setups generated by AI based on today's BIIB price and gamma walls.
